Clinical Trial Update: An Open-label, Time-lagged, Dose-escalation Study to Evalaute the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa. [EARLY_Phase 1]

View source ↗

Summary

An open-label, dose-escalation Phase 1 study is evaluating the safety and efficacy of subcutaneous siplizumab for hidradenitis suppurativa, and the trial is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Siplizumab (siplizumab)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Hidradenitis Suppurativa | EARLY_Phase 1 | Status: RECRUITING